FDA Approved: DALIRESP — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approves a supplemental application for Daliresp (roflumilast) submitted by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daliresp (roflumilast)

Snippet

SUPPL AP for DALIRESP (ROFLUMILAST)